iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12

iBio, Inc.

Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.
First participant dosing expected in second quarter 2026.
IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass in obesity, with potential for 2-4 doses per year.
Series G warrants (outstanding ~27.9M shares) will expire on May 12, 2026 – 30 trading days after this public announcement.
If all Series G warrants exercised, an additional ~27.9M common shares issued plus Series H warrants for same amount.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.